“The effectiveness of a vaccine consists of its immunological effectiveness and preventive effectiveness.
According to the results of the 1st and 2nd phases of CI, the immunological efficacy of the EpiVacCorona vaccine is 100%, "RIA Novosti quotes the agency.
Earlier, Russian Deputy Prime Minister Tatyana Golikova said that a large-scale production of the EpiVacCorona coronavirus vaccine would begin in February.
On January 19, the State Research Center for Virology and Biotechnology "Vector" gave details about EpiVacCorona.